Χώρα: Κύπρος
Γλώσσα: Ελληνικά
Πηγή: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
DOBUTAMINE HYDROCHLORIDE
MYLAN S.A.S. (0000003678) 117 ALLEE DES PARCS, SAINT PRIEST, 69800
C01CA07
DOBUTAMINE
250MG/20ML
CONCENTRATE FOR SOLUTION FOR INFUSION
DOBUTAMINE HYDROCHLORIDE (0052663817) 280MG
INTRAVENOUS USE
Ειδική άδεια άρθρο 126A
DOBUTAMINE
Νομικό καθεστώς: Με Ιατρική Συνταγή; PACK WITH 10 AMPS X 20ML (26S026301) 10 AMPOULE - Εγκεκριμένο - Με Ιατρική Συνταγή
LEAFLET ANSM - Mis à jour le : 24/07/2017 DOBUTAMINE MYLAN 250 MG/20 ML, CONCENTRATE FOR SOLUTION FOR INFUSION DOBUTAMINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. _ _ WHAT IS IN THIS LEAFLET: 1. What DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for solution for infusion is and what it is used for 2. What do you need to know before you use DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for solution for infusion 3. How to use DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for solution for infusion 4. Possible side effects 5. How to store DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for solution for infusion 6. Further information 1. WHAT DOBUTAMINE MYLAN 250 MG/20 ML, CONCENTRATE FOR SOLUTION FOR INFUSION IS AND WHAT IT IS USED FOR A DOPAMINERGIC AND ADRENERGIC CARDIAC STIMULANT (C01CA07: cardiovascular system) This medicinal product is recommended for the treatment of the following cases: Syndromes with low cardiac output: during or after cardiac surgical procedure; toxic-infectious shock ; myocardial infarction ; serious pulmonary embolism ; valvular heart disease and non-obstructive cardiomyopathy during episodes of cardiac decompensation; change in cardiac preload associated with high levels of end-expiratory positive pressure. Can be used in cardiovascular functional investigation when an exercise test is not feasible or is insufficient. Paediatric population Dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac o Διαβάστε το πλήρες έγγραφο